Skip to Content
Merck
All Photos(1)

Documents

S-018

Supelco

Sufentanil-D5 solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22D5H25N2O2S
CAS Number:
Molecular Weight:
391.58
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

100 μg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

[2H]C([2H])(C)C(=O)N(c1ccccc1)C2(CCN(CCc3cccs3)CC2)COC

InChI

1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3/i3D2

InChI key

GGCSSNBKKAUURC-SMZGMGDZSA-N

General description

Sufentanil is a short acting synthetic opioid analgesic used as a painkiller during medical operations. This stable-labeled internal standard is suitable for quantitation of sufentanil levels in urine, serum, or plasma by LC/MS or GC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or isotope dilution methods. Sufentanil is sold under the trade name Sufenta.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Fechner et al.
European journal of pain (London, England), 17(4), 562-570 (2012-08-29)
There is an ongoing debate whether opioids when used for intra-operative analgesia may enhance post-operative pain. We studied the effect of two different intra-operative dosings of sufentanil on post-operative morphine consumption, pain and hyperalgesia after cardiac anaesthesia. Forty-two male patients
Robert Stephen et al.
Journal of opioid management, 8(4), 237-241 (2012-09-04)
In emergency medicine, the ability to provide rapid, adequate pain control without high resource utilization is ideal. In this study, the efficacy of intranasal sufentanil in emergency department (ED) patients with acute distal extremity injury was evaluated. A nonrandomized, open-label
Marc Lilot et al.
Anesthesia and analgesia, 117(1), 259-264 (2013-04-18)
In this randomized, prospective trial, we sought to determine the effective dose of hypobaric ropivacaine with sufentanil providing 95% success (ED95) in spinal anesthesia for traumatic femoral neck surgery in the elderly. Sixty-eight elderly patients with unilateral hip fracture randomly
Xin Wang et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 21(5), 1140-1145 (2012-12-12)
To evaluate the effect of combined local anaesthetic and opioid in post-operative analgesia, the effect of intra-articular injection of local anaesthetic (ropivacaine), opioid (sufentanil) and combination of these two (ropivacaine combined with sufentanil) after the single-bundle anterior cruciate ligament reconstruction
S Karason et al.
Acta anaesthesiologica Scandinavica, 57(5), 639-645 (2013-02-26)
Bladder catheterisation may be inconvenient for patients, delay mobilisation and risk complications. We hypothesised that by excluding pre-operatively patients at high risk of post-operative urinary retention, the majority of patients could avoid perioperative catheterisation during low-dose spinal anaesthesia. Patients undergoing

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service